Malignant tumor complicated with chronic kidney disease?Chronic kidney disease
Conditions
Interventions
Tumor Patients – Control Group:Standard treatment
Tumor Patients – Ketogenic Diet:Add a ketogenic diet
Tumor Patients – Ketogenic Health Products:Add ketogenic health food products
CKD Patients – Control Group:Standard treatment
CKD Patients – Ketogenic Health Products:Add ketogenic health food products
CKD Patients – Ketogenic Diet:Add a ketogenic diet
Sponsors
Longyan First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18 to 60 years old, regardless of gender. 2.Patients with malignant tumors: Pathologically confirmed as malignant tumors, and classified as CKD stage 3–5 according to the CKD staging criteria. Patients with simple chronic kidney disease (CKD): Meeting the diagnostic criteria for CKD, and classified as CKD stage 3–5. 3.Before enrollment, the cardiopulmonary function is relatively stable, with no complicated severe infection, clear consciousness, and the ability to listen, speak, and answer questions. 4.Patients who have provided informed consent, been confirmed by clinicians to have no severe complications, and are eligible for study participation.
Exclusion criteria
Exclusion criteria: 1.Congenital metabolic disease. 2.Major organ diseases, including: history of pancreatitis, active gallbladder disease, moderate to severe liver dysfunction (Child-Pugh class B or above), frequent gout, lipodystrophy, severe heart or lung disease, etc. 3.Uncontrolled diabetes (fasting blood glucose > 8.3 mmol/L or glycated hemoglobin > 8.0%), malnutrition, intolerance to ketogenic diet, hypersensitivity to ingredients of ketogenic health food products, inability to take care of oneself, and failure to complete follow-up on schedule. 4.Abnormal blood pressure: severe hypertension (e.g., blood pressure > 180/110 mmHg) or hypotension ( 55 mmHg); active or suspected myocarditis or pericarditis; suspected or known dissecting aneurysm; thrombophlebitis and recent systemic or pulmonary embolism.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood Ketone Body Concentration;Urine Ketone Body Concentration;Bone Mineral Density; | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver function;Electrolyte;Complete Blood Count;Routine urine test;Renal function; | — |
Countries
China
Contacts
Public ContactBaoling Guo
Longyan First Hospital
Outcome results
None listed